With cell therapy showing more promise lately, Unum Therapeutics Inc.'s series A funding will help advance its platform for cancer treatment based on an antibody-coupled T-cell receptor (ACTR), in which T cells are genetically programmed so that they can go after a variety of cancers via targeting antibodies, and are not restricted by a particular antigen.
The ACTR approach differs from others that are limited to a single target and thus can treat only a narrow set of tumors. That is where the firm's name comes from Latin, meaning "one," most commonly heard in the phrase "e pluribus unum," meaning "out of many, one."
ACTR "takes advantage of CD16, which is really part of the therapy itself," said Unum CEO Charles Wilson. "The way it works is essentially to create a modified T cell that expresses a